<DOC>
	<DOCNO>NCT02602990</DOCNO>
	<brief_summary>A non-interventional multicentric study patient cerebral AVM endovascular treatment indicate .</brief_summary>
	<brief_title>Treatment Cerebral Arteriovenous Malformations With SQUID™ Liquid Embolic Agent</brief_title>
	<detailed_description>This observational study collect data treatment rupture , unruptured , untreated endovascular previously treat AVM 's . Primary endpoint safety . Safety assess number procedure-related complication occur endovascular treatment 30 day final embolization . Secondary endpoint efficacy . Efficacy assess angiography clinical outcome assessment ( mRS ) . For patient enrol , data collect inclusion , embolization session 6 ± 1 month end endovascular treatment phase .</detailed_description>
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Arteriovenous Malformations</mesh_term>
	<mesh_term>Hemangioma</mesh_term>
	<mesh_term>Intracranial Arteriovenous Malformations</mesh_term>
	<criteria>1 . Patient must sign informed consent form prior indexprocedure . If patient unable provide patient 's medical condition , informed consent patient 's legally authorize representative shall request . 2 . The patient untreated endovascular previously treat cerebral AVM endovascular treatment indicate . 3 . The patient least 18 year old . 1 . Patient pregnant . 2 . Patient renal insufficiency ( GFR &lt; 45 ml/min/1.73 m² )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Cerebral</keyword>
	<keyword>Arteriovenous</keyword>
	<keyword>Malformation</keyword>
	<keyword>Embolization</keyword>
	<keyword>Endovascular</keyword>
</DOC>